BeiGene, Ltd.
Research BeiGene, Ltd. (688235.SS) on Bullrun: market cap CNY 426.15B, P/E 69.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker688235.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 426.15B
- P/E69.3
- Financial periodQ2 2026
- RevenueUSD 1.71B
- Net incomeUSD 237.01M
- Free cash flowUSD 414.83M
- Gross margin89.8%
Valuation Snapshot
latest market cap is CNY 426.15B; P/E is 69.3.
Peer valuation comparison
Latest P/E is 69.32x versus a Healthcare sector median of 21.8x (218.0% above).
Latest P/E is 69.32x versus a China median of 16.46x (321.1% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 426.15B | 69.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CNY.
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BeiGene, Ltd.'s market cap?
BeiGene, Ltd.'s market capitalization is CNY 426.15B.
What is BeiGene, Ltd.'s P/E ratio?
BeiGene, Ltd.'s price-to-earnings (P/E) ratio is 69.3.
What does BeiGene, Ltd. do?
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.